Why the study?
Does discontinuation of β-blockers beyond 1 year after AMI increase the risk of death or readmission for ACS in revascularized patients without heart failure?
Population
Patients without heart failure, revascularized and optimally treated after acute myocardial infarction (AMI)
Design
Cohort
Authors
Loading...
May warrant caution discontinuing β-blockers beyond 1 year post-AMI in revascularized patients without HF; leaves open need for RCTs to confirm.
Does discontinuation of β-blockers beyond 1 year after AMI increase the risk of death or readmission for ACS in revascularized patients without heart failure?
Discontinuing beta-blockers beyond 1 year after AMI in revascularized patients without heart failure may increase the risk of death or ACS readmission.
Neumann et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: